SignalCorporate

NOVOZYMES Q2 REVENUE UP 9.8% Y/Y; RAISES FY26 ORGANIC SALES GROWTH OUTLOOK, INAUGURAL €1B SHARE BUYBACK PLAN - SEEKINGALPHA

Q2 revenue up 9.8% Y/Y, raised FY26 outlook, and inaugural €1B buyback.

What changed

Q2 revenue up 9.8% Y/Y, raised FY26 outlook, and inaugural €1B buyback.

Why it matters

Q2 revenue up 9.8% Y/Y, raised FY26 outlook, and inaugural €1B buyback. — impact context not separately stored; see What changed.

Sources